APOC3 and familial chylomicronemia syndrome: Results from the recent APPROACH trial, a 52-week randomized, double-blind, phase 3 trial of volanesorsen-mediated inhibition of APOC3 expression in 66 patients with familial chylomicronemia syndrome, showed that volanesorsen induced a 77% decrease in mean triglyceride levels (mean decrease of 19.3 mmol/l), whereas patients receiving placebo had an 18% increase in mean triglyceride levels.